The discovery of somatic cell nuclear transfer proved that somatic cells can carry the same
genetic code as the zygote, and that activating parts of this code are sufficient to reprogram …

Cardiovascular diseases are the leading cause of death worldwide. Therefore, the discovery
of induced pluripotent stem cells (iPSCs) and the subsequent generation of human induced …

The limitations of traditional two-dimensional (2D) cultures and animal testing, when it
comes to precisely foreseeing the toxicity and clinical effectiveness of potential drug …

Human iPS cell (iPSC)-derived cardiomyocytes (CMs) hold promise for drug discovery for
heart diseases and cardiac toxicity tests. To utilize human iPSC-derived CMs, the …

Organoids represent one of the most important advancements in the field of stem cells
during the past decade. They are three-dimensional in vitro culturing models that originate …

The convergence of tissue engineering and patient-specific stem cell biology has enabled
the engineering of in vitro tissue models that allow the study of patient-tailored treatment …

Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain
significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit …

Heart disease is a significant burden on global health care systems and is a leading cause
of death each year. To improve our understanding of heart disease, high quality disease …

The call for a paradigm change in toxicology from the United States National Research
Council in 2007 initiates awareness for the invention and use of human‐relevant alternative …

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) are commercially
available, and cardiac differentiation established routine. Systematic evaluation of several …